Protara Therapeutics

Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protaras portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com

Rare diseases,parenteral nutrition,choline deficiency,metabolic diseases,orphan diseases,gastrointestinal diseases,short bowel syndrome,drug development,corporate development,non-muscle invasive bladder cancer,and lymphatic malformations

Protara therapeutics operates in the Biotechnology research industry.

Protara therapeutics's revenue is 11m - 100m

Protara therapeutics has 11 - 50 employees.